Literature DB >> 14989124

Normal tissue tolerance to intraoperative radiotherapy.

William F Sindelar1, Timothy J Kinsella.   

Abstract

Much experimental evidence has been accumulated assessing the tolerance of various tissues to IORT, and much of the tolerance data have resulted from the use of canine models. Guidelines of IORT tissue tolerance established in experimental models have been used in the clinical application of IORT at numerous institutions. Although the radiotolerance of differing tissues can vary among species, sufficient clinical experience has accumulated to validate the canine tissue tolerance model as representative of human tissue responses to IORT. Cellular effects from radiation principally stem from direct damage to DNA, and thus proliferating tissues are among the most radiosensitive, with arrested or abnormal cell division. These tissues can manifest striking early toxicity, reflecting the rate of cell division that is affected by the radiation. Irradiation of nonproliferating or slowly proliferating tissues may show little or no early toxicity, but late effects can be manifested to considerable and varying degrees. In much of this late toxicity, pathologic changes develop from progressive ischemia, brought about by the gradual obliteration of small blood vessels. Irradiated endothelium often becomes replaced by a thickened fibrous layer, which, in small vessels, leads to occlusion and ischemic necrotic changes in the supplied tissue. In larger vessels, fibrosis can lead to wall weakening and aneurysmal dilatation, rupture, or thrombosis. The common denominator, then, of radiation damage to many tissues is related to vascular effects. Although the tolerance to IORT-induced toxicity can vary considerably among tissues, doses ranging to 25 Gy can generally be tolerated without significant toxicity. Vital areas where IORT dose must be carefully monitored include critical vasculature, gastrointestinal viscera, ureter, significant motor or sensory nerve trunks, and central nervous system structures. Higher doses can generally be delivered safely to anatomic areas at risk for tumor that are at a distance from sensitive organs or tissues. The general principle providing the rationale of IORT should always be practiced: maximize the radiation dose to the tumor and tumor-harboring tissues while minimizing dose exposure to surrounding normal tissues.

Entities:  

Mesh:

Year:  2003        PMID: 14989124     DOI: 10.1016/s1055-3207(03)00087-5

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  19 in total

1.  Radiation exposure and coronary atherothrombosis.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-12       Impact factor: 2.300

2.  Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them?

Authors:  Sunil Krishnan; Mediha Ahmad
Journal:  J Gastrointest Oncol       Date:  2013-12

Review 3.  [Pathogenesis of urological complications after radiation therapy].

Authors:  Y Tolkach; G Kristiansen
Journal:  Urologe A       Date:  2017-03       Impact factor: 0.639

4.  Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes.

Authors:  F A Calvo; C V Sole; R Obregón; M Gómez-Espí; C González-San Segundo; L González-Bayón; E Alvarez; J L García-Sabrido
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

5.  Intraoperative radiation therapy as adjuvant treatment in locally advanced stage tumours involving the middle ear: a hypothesis-generating retrospective study.

Authors:  G Cristalli; G Mercante; L Marucci; A Soriani; S Telera; G Spriano
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-04-29       Impact factor: 2.124

6.  Intraoperative electron radiation therapy as an important treatment modality in retroperitoneal sarcoma.

Authors:  Raeshell S Sweeting; Allison M Deal; Omar H Llaguna; Brian K Bednarski; Michael O Meyers; Jen Jen Yeh; Benjamin F Calvo; Joel E Tepper; Hong Jin Kim
Journal:  J Surg Res       Date:  2013-05-29       Impact factor: 2.192

7.  Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis.

Authors:  Sunil Sheth; Wissam Bleibel; Chandrashekhar Thukral; Yousif A-Rahim; Guido Beldi; Eva Csizmadia; Simon C Robson
Journal:  Purinergic Signal       Date:  2009-04-01       Impact factor: 3.765

8.  Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study.

Authors:  Timothy M Zagar; Robert R Shenk; Julian A Kim; Deb Harpp; Charles A Kunos; Fadi W Abdul-Karim; William C Chen; Yuji Seo; Timothy J Kinsella
Journal:  J Oncol       Date:  2009-01-29       Impact factor: 4.375

9.  Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy.

Authors:  Elizabeth J Sutton; Ricky T Tong; Amy M Gillis; Tobias D Henning; Vivian A Weinberg; Sophie Boddington; Daphne A Haas-Kogan; Katherine Matthay; Vinil Sha; Charles Gooding; Fergus V Coakley; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2009-09-18

10.  Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus.

Authors:  Jian-Jun Luo; Zi-Han Zhang; Qing-Xin Liu; Wen Zhang; Jian-Hua Wang; Zhi-Ping Yan
Journal:  Hepatol Int       Date:  2015-09-04       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.